Medicenna Therapeutics Corp (MDNAF)

$0.59 -0.01 (-2.15%)
Market Cap 50.05M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,900
Avg Vol 128,934
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 7%
Beta 1.81
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 648 5555
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
Lytnup
Lytnup Apr. 2 at 7:55 PM
$MDNAF David’s latest offering: https://open.substack.com/pub/davidbakke/p/the-repair-layer-world-re-eligibility?r=10wt7d&utm_medium=ios
0 · Reply
_Osmium
_Osmium Apr. 1 at 11:47 AM
$MDNAF Here's an idea I've likely mentioned prior: You have no cash, can't seem to attract institutional money; it's time to consider merging with another company. Raising money near all-time lows is irresponsible. Do current shareholders a favor.
0 · Reply
only1de
only1de Mar. 31 at 7:12 PM
$SGMO I hope if forced, $SGMO goes delisting rather than a reverse. $MDNAF did that at $.15 and after it went as high as $2. You can always go back to Nasdaq when ready. I’ve only had one reverse in biotech that helped the stock. All others were a disaster.
1 · Reply
Lytnup
Lytnup Mar. 27 at 2:17 PM
$MDNAF Looks like they streamlined the corporate slide deck for March https://ir.medicenna.com/static-files/f4748b19-5500-4d9e-b2d4-0c08830b627c Roth ✅ Bio space (Portugal) ✅ Next up: AACR
1 · Reply
Babara8290
Babara8290 Mar. 25 at 3:52 PM
$MDNAF https://finance.yahoo.com/news/merck-create-separate-cancer-business-112250919.html. Merck just bought a cancer biotech for $6.7B.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Mar. 25 at 3:32 PM
$MDNAF don’t expect much from this apparent data dump of 113. The last update in Jan was pretty much it… they already showed safety and good pd/pk in monkeys.
0 · Reply
Lytnup
Lytnup Mar. 25 at 3:02 PM
$MDNAF While we continue to see 52-week lows on meager volume, some more perspective from David. https://open.substack.com/pub/davidbakke/p/the-year-of-the-bispecific-and-the?r=10wt7d&utm_medium=ios
0 · Reply
Biosectors
Biosectors Mar. 25 at 2:49 PM
$MDNAF Hear you. long since late 2021 and still hopeful that the pipeline and 113 is an asset for big pharma. The management has bought in 2 experts in M & A let’s see after April 21st 113 read out and Optimus dosage feedback from FDA will turn this around. Merck need this for Keytruda patent extension based on the solid results so far. They may be waiting to buy for a song than paying replacement value playing on the cash on hand with Medicenna game.
0 · Reply
boomshiva
boomshiva Mar. 25 at 2:21 PM
$MDNAF The shakeout going into next month is fierce!
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Mar. 24 at 11:08 PM
$MDNAF Yeah getting sick and tired of these news releases of all the action in the “space”. Reeks of desperation ‘Hey what about me? What about me ?’. Either there is zero interest in the true data or management is the shits. Fahar himself said that he is loath to dilute…well yes but that’s the only way they’re getting cash! 55 has gone nowhere and 11 seems to have the same fate. Unfortunately we are starting at square one with 113 and need 100million plus 4 years min to get that to a Ph2… And let me guess there was “ tonnes of interest” at Roth today…
2 · Reply
Latest News on MDNAF
No data available.
Lytnup
Lytnup Apr. 2 at 7:55 PM
$MDNAF David’s latest offering: https://open.substack.com/pub/davidbakke/p/the-repair-layer-world-re-eligibility?r=10wt7d&utm_medium=ios
0 · Reply
_Osmium
_Osmium Apr. 1 at 11:47 AM
$MDNAF Here's an idea I've likely mentioned prior: You have no cash, can't seem to attract institutional money; it's time to consider merging with another company. Raising money near all-time lows is irresponsible. Do current shareholders a favor.
0 · Reply
only1de
only1de Mar. 31 at 7:12 PM
$SGMO I hope if forced, $SGMO goes delisting rather than a reverse. $MDNAF did that at $.15 and after it went as high as $2. You can always go back to Nasdaq when ready. I’ve only had one reverse in biotech that helped the stock. All others were a disaster.
1 · Reply
Lytnup
Lytnup Mar. 27 at 2:17 PM
$MDNAF Looks like they streamlined the corporate slide deck for March https://ir.medicenna.com/static-files/f4748b19-5500-4d9e-b2d4-0c08830b627c Roth ✅ Bio space (Portugal) ✅ Next up: AACR
1 · Reply
Babara8290
Babara8290 Mar. 25 at 3:52 PM
$MDNAF https://finance.yahoo.com/news/merck-create-separate-cancer-business-112250919.html. Merck just bought a cancer biotech for $6.7B.
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Mar. 25 at 3:32 PM
$MDNAF don’t expect much from this apparent data dump of 113. The last update in Jan was pretty much it… they already showed safety and good pd/pk in monkeys.
0 · Reply
Lytnup
Lytnup Mar. 25 at 3:02 PM
$MDNAF While we continue to see 52-week lows on meager volume, some more perspective from David. https://open.substack.com/pub/davidbakke/p/the-year-of-the-bispecific-and-the?r=10wt7d&utm_medium=ios
0 · Reply
Biosectors
Biosectors Mar. 25 at 2:49 PM
$MDNAF Hear you. long since late 2021 and still hopeful that the pipeline and 113 is an asset for big pharma. The management has bought in 2 experts in M & A let’s see after April 21st 113 read out and Optimus dosage feedback from FDA will turn this around. Merck need this for Keytruda patent extension based on the solid results so far. They may be waiting to buy for a song than paying replacement value playing on the cash on hand with Medicenna game.
0 · Reply
boomshiva
boomshiva Mar. 25 at 2:21 PM
$MDNAF The shakeout going into next month is fierce!
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Mar. 24 at 11:08 PM
$MDNAF Yeah getting sick and tired of these news releases of all the action in the “space”. Reeks of desperation ‘Hey what about me? What about me ?’. Either there is zero interest in the true data or management is the shits. Fahar himself said that he is loath to dilute…well yes but that’s the only way they’re getting cash! 55 has gone nowhere and 11 seems to have the same fate. Unfortunately we are starting at square one with 113 and need 100million plus 4 years min to get that to a Ph2… And let me guess there was “ tonnes of interest” at Roth today…
2 · Reply
Pilotboy1985
Pilotboy1985 Mar. 24 at 8:43 PM
$MDNAF couldn't resist and bought 3,000 more shares this morning so I could average down to $1.56 CAD. I believe in the science, I just wish management would get their act together. Been in this since 2019 and I'm tired of waiting.
0 · Reply
Dipper2013
Dipper2013 Mar. 24 at 6:47 PM
$MDNAF hmmm... all I see is dumping with no support. Someone is unloading. Very sad
0 · Reply
Gobblin
Gobblin Mar. 24 at 4:41 PM
$MDNAF https://x.com/medicenna1/status/2036435372427591944?s=46
1 · Reply
Lytnup
Lytnup Mar. 24 at 2:37 AM
$MDNAF Not apples to apples, but it seems like M&As are still happening….for P1 compounds https://www.fiercebiotech.com/biotech/sanofi-returns-tces-territory-12b-pact-phase-1-stage-trispecific Why fight off cytokines when you can program them?
0 · Reply
Lytnup
Lytnup Mar. 22 at 8:03 PM
$MDNAF The latest in David’s essays: https://open.substack.com/pub/davidbakke/p/operationalizing-layer-2-sub-layer?r=10wt7d&utm_medium=ios Light reading while we wait for AACR….
0 · Reply
Brocseg3
Brocseg3 Mar. 20 at 5:26 PM
$MDNAF https://open.substack.com/pub/biotechdistilled/p/medicenna-therapeutics-mdnaf-scientific?utm_source=share&utm_medium=android&r=2i05g6
1 · Reply
NewbJackCity
NewbJackCity Mar. 19 at 5:18 PM
$MDNAF I’ve always prided myself in spotting smaller biotechs that go after the so-called holy grails of oncology (e.g., kras, myc). I honestly didn’t come to Medicenna for their potential in targeting cold tumors. Interesting stuff..
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Mar. 18 at 1:00 PM
$MDNAF https://ir.medicenna.com/news-releases/news-release-details/medicenna-present-preclinical-data-its-first-class-tumor
1 · Reply
boomshiva
boomshiva Mar. 16 at 4:43 PM
$MDNAF Hard to stomach this SP after spending all of November at $1 or above.
0 · Reply
Lytnup
Lytnup Mar. 13 at 5:25 PM
$MDNAF - Secure FDA guidance on first potential registrational trial of MDNA11 in at least one advancer cancer indication in 2L/3L setting post-ICI therapy, including dose selection for Project Optimus - File an investigational new drug (IND) application for MDNA113 in H2 2026 and initiate a Phase 1/2a trial by Q4 2026 Strengthen the balance sheet through partnership and/or financing by mid-2026 in preparation for registrational trial for MDNA11 and commence FIH trial for MDNA113 - Present new pre-clinical and clinical data on bizaxofusp and IL-4Ralpha biology in recurrent GBM in Q1, 2026 Advance and close a strategic collaboration or partnership for bizaxofusp in 2026 - Strengthen management team and board of directors throughout 2026 GLTA -
2 · Reply
Lytnup
Lytnup Mar. 13 at 5:24 PM
$MDNAF It’s hard to know who is selling, or why there is such a lack of support for a company who continues to present best in class data. As a long term shareholder, it’s equally hard to watch. Unfortunately, there simply isn’t much to do but wait for Dr. Merchant to find a suitor / partner, or raise more money to pursue their latest goals for 2026: - Complete patient enrollment in ABILITY-1 study in MDNA11 monotherapy and combination arms across prioritized indications ( cutaneous melanoma, endometrial cancer, MSI-H/dMMR and MSS/TMB-H cancers) including any new expansion cohorts (for eg, CRC and NSCLC) with a focus on 2L/3L in post–anti-PD1 settings - Report updated clinical data from MDNA11 monotherapy and combination expansion cohorts including 2L/3L and last-line anti-PD1–treated patients enrolled within the ABILITY-1 study - Share interim clinical data from the Phase 1/2 study of MDNA11 in neoadjuvant melanoma trial (NEO-CYT) throughout 2026
1 · Reply
boomshiva
boomshiva Mar. 13 at 5:01 PM
$MDNAF 7% on 72 000 shares......smells like someone's bailed.
0 · Reply